NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases and Xerostomia, announced today second quarter results for the period ended September 30, 2006. The Company had revenue of $1,791,000, a 145% increase compared to $730,000 for the three months ended September 30, 2005. Revenue for the six months ended September 30, 2006 was $2,298,000, an increase of 206% compared to the prior year’s comparable period. The Company began operations in April, 2005. The increase in revenue was primarily attributable to higher sales of the Extendryl® line and the acquisition of the Levall® product line.
